Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Popa

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
Metabolites|March 27, 2026
Perioperative Intravenous Lidocaine and Early Biochemical Outcomes After Robotic-Assisted Radical Prostatectomy: A Clinical Study Within the Framework of Perioperative Metabolic-Inflammatory ModulationGeorgiana Maria Popa, Simona-Alina Abu-Awwad, Ahmed Abu-Awwad, et al.
Oncology Letters|January 19, 2018
Update on radionuclide therapy in oncologyCornelia Nitipir, Dana Niculae, Cristina Orlov, et al.
Scandinavian Journal of Gastroenterology|July 5, 2021
Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseasesMohamed Attauabi, Camilla Höglund, Janne Fassov, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
Metabolites|March 27, 2026
Perioperative Intravenous Lidocaine and Early Biochemical Outcomes After Robotic-Assisted Radical Prostatectomy: A Clinical Study Within the Framework of Perioperative Metabolic-Inflammatory ModulationGeorgiana Maria Popa, Simona-Alina Abu-Awwad, Ahmed Abu-Awwad, et al.
Oncology Letters|January 19, 2018
Update on radionuclide therapy in oncologyCornelia Nitipir, Dana Niculae, Cristina Orlov, et al.
Scandinavian Journal of Gastroenterology|July 5, 2021
Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseasesMohamed Attauabi, Camilla Höglund, Janne Fassov, et al.
Pageof 8